Skip to content

Meditation based lifestyle modification (MBLM) in outpatients with mild to moderate depression: A mixed-methods feasibility study.

Holger C Bringmann, Nicole Bringmann, Michael Jeitler, Stefan Brunnhuber, Andreas Michalsen, Peter Sedlmeier

Complementary Therapies in Medicine November 16, 2020 DOI: 10.1016/j.ctim.2020.102598 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Single-arm mixed-methods feasibility study Qualitative Peer reviewed
Sample size 25
Population Outpatients with mild or moderate depression in psychiatric care
Intervention Meditation Based Lifestyle Modification (MBLM)
Duration Intervention period (exact duration not stated in abstract)
Topics Depression Meditation
Citations 16
Key points MBLM is a highly acceptable and feasible program for outpatients with mild to moderate depression, associated with a clinically important decrease in depressive symptoms and improved well-being.

Abstract

Background: Integrative mental health care can be used to treat depression with a person-centered, lifestyle-modifying, and more salutogenic approach to mental health and human flourishing. In this article, we report on the feasibility and acceptability of a new mind-body program, Meditation Based Lifestyle Modification (MBLM), in outpatients with mild or moderate depression.

Methods: This is a single-arm mixed-methods feasibility study of n = 25 outpatients in psychiatric care. Depressive symptoms, scores for mindfulness, aspects of spirituality, and eudaemonic well-being based on yoga philosophy were assessed at baseline and at the end of the intervention. Adherence was monitored and face-to-face interviews were held after the program to explore the acceptability and feasibility of MBLM.

Results: Twenty patients (75 %) completed at least six sessions of the course. Adherence was 87.5 % of allocated sessions. In qualitative analysis, more than half of the participants experienced novelty and inspiration through practicing the ethical aspects of yoga (e.g., nonviolence, truthfulness, etc.). Almost all participants experienced a decrease in emotional distress. Virtually all participants reported more self-confidence and self-acceptance. In quantitative analysis, participants reported a clinically important decrease in depressive symptoms of 39.23 % (p = .002), eudaemonic well-being increased significantly in a range of related scales and scores for mindfulness increased (p < .001).

Conclusion: MBLM is a highly acceptable and feasible program for outpatients with mild to moderate depression. This comprehensive, lifestyle-modifying approach is highly relevant to preventing and treating mental illness, and treating psychic comorbidities in patients with chronic somatic illness.

Comparable studies

Other non-randomized and open-label trials on depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Patients with recurrent depression 2015 Open-label trial n = 17

Citations in the library

Cited by 9

and 4 more in the library

Cites 11

and 6 more in the library

Explore topics